Our findings that VISTA+ Tfr cells suppress effector immune cell function further support the rationale for VISTA-targeted therapies: inhibiting VISTA may not only directly activate T cells but also disrupt the immunosuppressive effects of Tfr cellstsuppress a “ells hitl to enhance anti-tumor immunity. This evidence concerns the gene TFRC and neoplasm.